相关实验视频

Updated: May 14, 2025

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

在患有子宫内膜异位症的患者中,黄素对迪诺杰斯特的附加作用:一种随机,双盲,受控试验

Mahjoob Sargazi-Taghazi¹, Habib Ghaznavi², Roghayeh Sheervalilou²

¹Department of Obstetrics and Gynaecology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.

Phytomedicine : international journal of phytotherapy and phytopharmacology

|April 12, 2025

概括

将黄素添加到 dienogest 显著改善了子宫内膜异位症妇女的疼痛,生活质量和性功能. 这种组合疗法为治疗这种慢性妇科疾病提供了一种有前途的新方法.

科学领域:

妇科妇科妇科妇科
药理学药理学是指药理学的学科.
自然产品研究自然产品研究

背景情况:

子宫内膜异位症显著影响生活质量 (QOL),目前的治疗方法往往无法充分管理.
黄素在子宫内膜异位症治疗中显示出临床前的前景,但其作为辅助疗法的临床疗效在很大程度上尚未被探索.

研究的目的:

为了评估黄素与二诺日斯特结合的补充效应,以缓解子宫内膜异位症妇女的疼痛,QOL和性功能.
这是第一个随机对照试验来评估这种特定的组合疗法.

主要方法:

一个随机,双盲,安慰剂对照试验,涉及86名女性 (18-45岁) 患有2-3期子宫内膜异位症和中度至重度疼痛.
参与者接受了纳米库尔库 (80毫克/天) 或安慰剂,并与丁诺 (2毫克/天) 一起服用8周.

主要成果:

与安慰剂+安慰剂相比,黄素+二诺日斯特组显示出明显更大程度的降低了异常发作,异常发作,慢性骨盆疼痛和异常发作.
在整体QOL和女性性功能指数 (FSFI) 得分上也注意到了改善,但不包括高潮领域.
两组之间没有观察到子宫内膜瘤大小的显著差异.

结论:

黄素作为dienogest的补充剂显著减轻疼痛,并提高QOL和性功能在女性内膜异位症.
这种组合疗法代表了对子宫内膜异位症管理的潜在有效治疗策略.

关键词:

库尔库明是一种黄素.这是最重要的服务.子宫内膜异位症是什么?子宫内膜异位症是什么疼痛疼痛疼痛疼痛生活质量生活的质量.

更多相关视频

Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis

Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis

Published on: February 26, 2019

Mouse Model of Surgically-induced Endometriosis by Auto-transplantation of Uterine Tissue

Mouse Model of Surgically-induced Endometriosis by Auto-transplantation of Uterine Tissue

Published on: January 6, 2012

相关概念视频

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Oogenesis

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...